Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
Condition:   Breast Cancer Interventions:   Biological: GBR 1302 250 ng/kg;   Biological: GBR 1302 325 ng/kg;   Biological: GBR 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22;   Biological: GBR 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22;   Biological: GBR1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22;   Biological: GBR1302 325ng/kg D1;55 0 ng/kg D8;900 ng/kg D15,22;   Biological: GBR1302 escalating doses,1200 ng/kg D15,22;   Biological: GBR1302 at the MTD and/or RP2D dose Sponsor:   Glenmark Pharmaceut...
Source: ClinicalTrials.gov - June 12, 2019 Category: Research Source Type: clinical trials

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer Intervention:   Radiation: Standard Trimodality Breast Imaging Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer Intervention:   Radiation: Standard Trimodality Breast Imaging Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer Intervention:   Radiation: Standard Trimodality Breast Imaging Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer Intervention:   Radiation: Standard Trimodality Breast Imaging Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer Intervention:   Radiation: Standard Trimodality Breast Imaging Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Feasibility of a New Technology for Isolating Circulating Tumour Cells
Conditions:   HER2-positive Metastatic Breast Cancer;   Ovarian Cancer;   Hormone-resistant Prostate Cancer;   Circulating Tumor Cell Intervention:   Procedure: Blood sample collection Sponsor:   Centre Oscar Lambret Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

A Study of Tucatinib vs. Placebo in Combination With Trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Condition:   HER2-positive Breast Cancer Interventions:   Drug: tucatinib;   Drug: placebo;   Drug: T-DM1 Sponsor:   Seattle Genetics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Condition:   NonSmall Cell Lung Cancer Intervention:   Drug: DZD9008 Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 4, 2019 Category: Research Source Type: clinical trials